Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Vertex provided 2025 revenue guidance of $11.75 billion to $12 billion, reflecting 8% growth at the midpoint. Growth is expected from U.S. launches of ALYFTREK and JOURNAVX, along with the continued ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Accumulation of clots causes some of the most severe symptoms of sickle cell disease, including strokes, kidney failure, ...

People living with sickle cell are apprehensive about a revolutionary new one-off treatment that has just been approved for use on the NHS. | ITV News Granada ...